CD274 and melanoma: Immune checkpoint inhibition (ICI) through blockage of cytotoxic T‐lymphocyte‐associated protein 4 (CTLA‐4) and programmed cell death ligand 1 (PD‐L1) or anti‐programmed cell death receptor 1 (anti PD‐1) has emerged as a highly efficacious therapeutic approach for stage IV melanoma due to the high immunogenicity of this tumor entity.